Showing results (1421-1430 of 1,689) with videos related to
Sort By:
Pageof 169
European Journal of Heart Failure|August 31, 2024
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.Journal of the American College of Cardiology|April 30, 2025
Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled AnalysisMaria A Pabon, Gerasimos Filippatos, Brian L Claggett, et al.European Journal of Heart Failure|April 29, 2025
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HFToru Kondo, Pardeep S Jhund, Alasdair D Henderson, et al.JAMA Cardiology|March 29, 2025
Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical TrialShingo Matsumoto, Alasdair D Henderson, Pardeep S Jhund, et al.JAMA Cardiology|May 21, 2025
Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical TrialMaria A Pabon, Orly Vardeny, Muthiah Vaduganathan, et al.Journal of the American College of Cardiology|August 30, 2022
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.JAMA Cardiology|May 20, 2023
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER TrialAlexander Peikert, Alvin Chandra, Mikhail N Kosiborod, et al.Circulation|March 6, 2023
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER TrialToru Kondo, Karola S Jering, C Jan Willem Borleffs, et al.European Heart Journal|November 20, 2024
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney diseaseJohn W Ostrominski, Mats C Højbjerg Lassen, Brian L Claggett, et al.European Journal of Heart Failure|March 15, 2024
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVERAlexander Peikert, Muthiah Vaduganathan, Brian L Claggett, et al.Pageof 169